Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

Executive Summary

FDA's internal disagreements about the value of GlaxoSmithKline's RECORD trial stem, in part, from different visions of the role agency reviewers should play in analyzing data

You may also be interested in...



FDA Polled Review Staff On Avandia REMS Changes

Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.

Avandia Review Endorsement Aided By Good Data, Cultural Shift On Safety

Flawed clinical trial overcomes meta-analysis safety signal as mortality data from the re-adjudicated RECORD trial persuades the rosiglitazone advisory committee that the product’s risk management program can be relaxed.

FDA Pushes For Scientific Integrity As Staff Criticize Corporate Influence In External Survey

The agency reiterates its commitment to protecting scientific integrity in response to the Union of Concerned Scientists’ survey of FDA scientists; staff cite corporate influence on agency decisions and fear of retaliation for expressing their concerns.

Related Content

Topics

UsernamePublicRestriction

Register

PS052431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel